Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;18(3):e143-e152.
doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Lesley Seymour  1 , Jan Bogaerts  2 , Andrea Perrone  3 , Robert Ford  4 , Lawrence H Schwartz  5 , Sumithra Mandrekar  6 , Nancy U Lin  7 , Saskia Litière  2 , Janet Dancey  8 , Alice Chen  9 , F Stephen Hodi  7 , Patrick Therasse  10 , Otto S Hoekstra  11 , Lalitha K Shankar  12 , Jedd D Wolchok  13 , Marcus Ballinger  14 , Caroline Caramella  15 , Elisabeth G E de Vries  16 ; RECIST working group
Affiliations
Review

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Lesley Seymour et al. Lancet Oncol. 2017 Mar.

Erratum in

Abstract

Tumours respond differently to immunotherapies compared with chemotherapeutic drugs, raising questions about the assessment of changes in tumour burden-a mainstay of evaluation of cancer therapeutics that provides key information about objective response and disease progression. A consensus guideline-iRECIST-was developed by the RECIST working group for the use of modified Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) in cancer immunotherapy trials, to ensure consistent design and data collection, facilitate the ongoing collection of trial data, and ultimate validation of the guideline. This guideline describes a standard approach to solid tumour measurements and definitions for objective change in tumour size for use in trials in which an immunotherapy is used. Additionally, it defines the minimum datapoints required from future trials and those currently in development to facilitate the compilation of a data warehouse to use to later validate iRECIST. An unprecedented number of trials have been done, initiated, or are planned to test new immune modulators for cancer therapy using a variety of modified response criteria. This guideline will allow consistent conduct, interpretation, and analysis of trials of immunotherapies.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests

LS reports grants from AstraZeneca and Merck, outside the submitted work. AP owns stocks in Merck & Co. RF reports personal fees from Amgen, Abbvie, Aptiv, Aragon, BMS, Bioclinica, Celldex, Celsion, Clovis, Covance, Biomedical systems, ACR Image Metrix, Exelixis, Genentech, Janssen, Kyowa, Loxo, ICON Medical Imaging, Eisai, EMD Serono, Imaging Endpoints, Mlrati, Celgene, Merck, Novartis, Novocure, Roche, Pfizer, Quintile, Tokai, ONO, Red Hill, Radiant Sage, Orbimed Advisors, Cinven, Virtualscopics, Sun Advanced Pharma Research Company, Median Therapeutics, Optimer Biotechnology Inc, Vascular Biogenics, Ignyta, Immunocellular CBT Pharmaceuticals, Tracon, DNAtrix, CytRx, Kolltan, and Samsung Bioepsis, outside the submitted work. LHS reports grants and consulting fees from Novartis, grants from Astellas, Eli Lilly, Merck, Pfizer, consulting fees from GSK, outside the submitted work. JD reports grants from Merck, AstraZeneca, Pfizer, Ottawa Hospital Research Institute, Novartis, outside the submitted work. FSH reports grants from Bristol-Myers Squibb, and personal fees from Merck, Novartis, Genentech, and EMD Serono, outside the submitted work. Additionally, FSH has a patent MICA Related Disorders with royalties paid, and a patent Tumor Antigens and Uses Thereof issued. JDW reports grants from Bristol Myers Squibb, Merck, and Genentech during the conduct of the study; consulting fees from Bristol Myers Squibb and Merck, and is on the scientific advisory board for Medimmune, outside the submitted work. MB reports personal fees from Genentech outside the submitted work, and owns stocks in Roche. CC reports personal fees from Roche, BMS, and AstraZeneca, outside the submitted work. EGEdV reports consulting fees from Synthon, Medivation, and Merck; and grants from Novartis, Amgen, Roche/Genentech, Servier, Chugai, Synthon, AstraZeneca, and Radius Health, outside the submitted work. JB, SM, NUL, SL, AC, PT, OSH, and LKS declare no competing interests.

Figures

Figure 1
Figure 1. Process for developing and validating iRECIST consensus guidelines
Blue shaded boxes represent steps still in progress. RECIST=Response Evaluation Criteria in Solid Tumours.
Figure 2
Figure 2. RECIST 1.1 and iRECIST: an example of assessment
Prefix “i” indicates immune responses assigned using iRECIST; others without “i” are confirmed by RECIST 1.1. RECIST=Response Evaluation Criteria in Solid Tumours. iCR=complete response. iCPD=complete progression. iPR=partial response. iSD=stable disease. iUPD=unconfirmed progression. TP=timepoint.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175:1992–94. - PubMed
    1. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14. - PubMed
    1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16. - PubMed
    1. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1·1) Eur J Cancer. 2009;45:228–47. - PubMed
    1. Liu Y, Litière S, de Vries EG, et al. The role of response evaluation criteria in solid tumor in anticancer treatment evaluation: results of a survey in the oncology community. Eur J Cancer. 2014;50:260–66. - PubMed

Publication types